# Mesoblast Ltd (MESO)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/mesoblast-ltd/ JSON: https://steadybase.io/company/mesoblast-ltd.json Checked Nov 21, 2026. Latest filing read: Aug 27, 2026.

## Company

- Legal name: MESOBLAST LTD
- Ticker: MESO, MEOBF (Nasdaq, OTC)
- SEC CIK: 0001345099
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Melbourne, Victoria, C3
- Fiscal year ends: June 30
- SEC filer category: Large accelerated filer
- Website: mesoblast.com
- LinkedIn: https://www.linkedin.com/company/mesoblast

## Key facts

- Revenue: $17.2M for the fiscal year ended Jun 30, 2025 (20-F filed Aug 29, 2025). Source: https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/0001345099-25-000067-index.html
- Net income: -$102.1M for the fiscal year ended Jun 30, 2025 (20-F filed Aug 29, 2025). Source: https://www.sec.gov/Archives/edgar/data/1345099/000134509925000067/0001345099-25-000067-index.html
- Employees: 108 as of Jun 30, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/meso-20260630.htm
- Shares outstanding: 1,296,862,776 as of Jun 30, 2026 (20-F filed Aug 27, 2026). Source: https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/0001345099-26-000081-index.html
- Auditor: Pricewaterhousecoopers, Melbourne, Australia, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/meso-20260630.htm

## Business

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Source: Press release "About" paragraph, https://www.sec.gov/Archives/edgar/data/1345099/000134509926000093/exhibit991activitystatem.htm

## Annual results

| Fiscal year ended | Revenue | Net income |
|---|---|---|
| Jun 30, 2025 | $17.2M | -$102.1M |
| Jun 30, 2024 | $5.9M | -$88.0M |
| Jun 30, 2023 | $7.5M | -$81.9M |
| Jun 30, 2022 | $10.2M | -$91.3M |
| Jun 30, 2021 | $7.4M | -$98.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/mesoblast-ltd.json

## Officers and directors

- Silviu Itescu, CEO and Managing Director. LinkedIn: https://linkedin.com/in/silviu-itescu-470855a. Source: Form 3 filed Apr 1, 2026, https://www.sec.gov/Archives/edgar/data/1345099/000121390026037945/0001213900-26-037945-index.htm
- James Michael Obrien, Chief Financial Officer. Source: Form 4 filed Jul 9, 2026, https://www.sec.gov/Archives/edgar/data/1345099/000121390026076893/0001213900-26-076893-index.htm
- Eric Allen Rose, Chief Medical Officer,Director. Source: Form 3 filed Mar 18, 2026, https://www.sec.gov/Archives/edgar/data/1345099/000121390026030107/0001213900-26-030107-index.htm

## Insider trades (Form 4)

- Apr 10, 2026: Gregory George (Director) bought 7,910,962 shares, about $11.4M. Source: https://www.sec.gov/Archives/edgar/data/1345099/000199937126008132/0001999371-26-008132-index.htm
- Apr 10, 2026: Gregory George (Director) bought 8,305,962 shares, about $26.1M. Source: https://www.sec.gov/Archives/edgar/data/1345099/000199937126008124/0001999371-26-008124-index.htm

## Latest filings

- 20f filed Aug 27, 2026: https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/meso-20260630.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

